Patients with advanced tumours exhibiting EGFR overexpression or EGFRvIII mutation were tested with ADC depatuxizumab mafodotin (depatux-m), a monoclonal antibody targeting the EGFR linked with agent monomethyl auristatin F, which binds to the vinca domain of tubulin and disrupts microtubule dynamics. The gene discussed is EGFR; the disease is neoplasm.